CA-XSOLLA
22.8.2024 10:01:27 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, proudly extends its strategic partnership with GameAnalytics, the leading analytics service for game developers and publishers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240822075172/en/
(Graphic: Xsolla)
The partnership marks a significant expansion of Xsolla's capabilities. By integrating GameAnalytics directly into the Xsolla Backend Solution, developers can access powerful analytics and monetization tools in one seamless interface. This integration redefines how developers approach game analytics and monetization, providing a comprehensive toolkit to enhance their understanding of player behavior, optimize revenue streams, and drive better business outcomes. Developers can now track critical metrics such as conversion rates, player retention, and lifetime value while leveraging Xsolla’s extensive payment processing capabilities, offering a unique advantage by combining data-driven insights and robust monetization tools under a single umbrella.
Jean-Philippe Steinmetz, Head of Xsolla Backend, highlights the strategic importance of expanding the partnership: “By incorporating GameAnalytics into Xsolla Backend, we are enhancing our platform's ability to deliver comprehensive game analytics and benchmarking. This collaboration allows us to provide developers with a deeper understanding of their games' performance, enabling them to make informed decisions that drive success.”
GameAnalytics, known for serving over 12,000 game studios and offering insights on more than 2.3 billion players each month, brings unparalleled expertise in analytics to this partnership. The integration with Xsolla Backend allows developers to access these insights effortlessly, providing a clear view of how their games perform across various metrics. This partnership enhances the analytic capabilities available to developers and simplifies integrating these insights with monetization strategies, ultimately helping developers maximize their revenue potential.
Allison Bilas, COO at GameAnalytics, expressed her enthusiasm for the expansion of the partnership: “We are excited to expand our relationship with Xsolla by integrating our analytics suite into Xsolla Backend. This integration allows us to deliver even more value to developers, helping them better understand their games and make data-driven decisions to enhance player experiences.”
The collaboration underscores Xsolla’s dedication to providing game developers with the tools they need to succeed in a competitive market. By combining the power and efficiency of Xsolla Backend with Xsolla's payment and monetization tools and GameAnalytics' industry-leading data analysis capabilities, developers now have access to a powerful, all-in-one solution that simplifies the process of building, tracking, and improving game performance.
For more information, please visit xsolla.pro/xbegameanalytics.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
About GameAnalytics
GameAnalytics is the leading analytics solution for developers, game studios, and powerhouse publishers globally. Their network covers 100,000 games played by over 1.75 billion people for an average of 24 billion monthly sessions. The GameAnalytics platform enables game development teams to rapidly refine gameplay, improve retention, and increase revenue with real-time data analysis for all major game engines and operating systems through a simple SDK integration. GameAnalytics was founded in 2012 by Danish serial entrepreneur Morten E. Wulff, who remains the company's Chairman today. After raising over $8M in funding, the leading mobile advertising company, Mobvista, acquired the company in 2016. To learn more and get started for free, visit gameanalytics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822075172/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom